The ESMO Preceptorship on NSCLC and SCLC 2025 in Singapore, taking place from 8 December 2025 to 9 December 2025, brings together oncology professionals to explore best practices in managing non-small-cell and small-cell lung cancer across all stages.

The programme covers the latest in targeted therapies, actionable driver alterations, immune checkpoint blockade, novel immunotherapies, and systemic treatment of SCLC and pleural mesothelioma. Accredited with 10 ESMO-MORA category 1 points, the preceptorship offers participants hands-on learning, expert insights, and a travel grant for non-local attendees to support participation.